Rhythm Pharmaceuticals Q4 Beat Sets Stage For March 20th PDUFA Decision

Financial Performance - Rhythm Pharmaceuticals reported a 4Q25 GAAP EPS of -$0.73, which exceeded estimates by approximately $0.07 [1] - Revenue for the quarter was $57.3 million, representing a nearly 37% year-over-year increase and $1.09 million above expectations [1] Future Expectations - For FY26, expectations indicate that Non-GAAP operating expenses will fall within a specified range, although the exact figures were not provided in the text [1]